Inhibition of interleukin-6 (IL-6) reverses anemia in patients with advanced non small cell lung cancer (NSCLC): Results of a phase II, randomized, double-blind, placebo-controlled trial

Category Primary study
JournalBlood
Year 2010
This article has no abstract
Epistemonikos ID: e8abbb8b0ca09a569ba86489c910407387e77318
First added on: Feb 05, 2025